PRISM Randomized Controlled Trial
Breast Cancer Screening
TrialActive
Key Facts
About ScreenPoint Medical
ScreenPoint Medical is a leader in AI-powered breast imaging diagnostics, with its Transpara platform being one of the most clinically validated solutions in the sector. The company's core value proposition is increasing cancer detection rates while reducing radiologist workload, addressing critical industry challenges like staff shortages and rising screening volumes. Transpara is vendor-agnostic, integrated into major clinical workflows, and is backed by extensive peer-reviewed research, including participation in multiple randomized controlled trials (RCTs). The company is privately held, commercially deployed in over 30 countries, and is positioned at the forefront of the rapidly growing AI diagnostics market.
View full company profileTherapeutic Areas
Other Breast Cancer Screening Drugs
| Drug | Company | Phase |
|---|---|---|
| Auria | Namida Lab | Commercial |
| Non-Contrast Breast MRI Screening Research | Ikonopedia | Research |
| Electrical Mammogram | NovaScan | Pre-clinical |
| Thermalytix | Niramai | Approved |
| KBCT for Primary Screening | Koning | Research / Aspirational |
| Breast Cancer Screening AI | Vara | Commercial |